<i>Pulmonary Circulation</i> <i>Pulmonary Circulation</i>
 Home | About us | Search | Ahead of Print | Current Issue | Past Issues | Instructions | Online submission | Contact us | Login 
Users Online: 49 Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size

 
REVIEW ARTICLE
Year : 2011  |  Volume : 1  |  Issue : 1  |  Page : 33-47

Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?


Department of Medicine, Emory University, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA

Correspondence Address:
C Michael Hart
Atlanta VA Medical Center (151),1670 Clairmont Road, Decatur, Georgia 30033
USA
Login to access the Email id


DOI: 10.4103/2045-8932.78101

PMID: 21547012

Get Permissions

Pulmonary hypertension (PH), a progressive disorder associated with significant morbidity and mortality, is caused by complex pathways that culminate in structural and functional alterations of the pulmonary circulation and increases in pulmonary vascular resistance and pressure. Diverse genetic, pathological, or environmental triggers stimulate PH pathogenesis culminating in vasoconstriction, cell proliferation, vascular remodeling, and thrombosis. We conducted a thorough literature review by performing MEDLINE searches via PubMed to identify articles pertaining to PPARγ as a therapeutic target for the treatment of PH. This review examines basic and preclinical studies that explore PPARγ and its ability to regulate PH pathogenesis. Despite the current therapies that target specific pathways in PH pathogenesis, including prostacyclin derivatives, endothelin-receptor antagonists, and phosphodiesterase type 5 inhibitors, morbidity and mortality related to PH remain unacceptably high, indicating the need for novel therapeutic approaches. Consequently, therapeutic targets that simultaneously regulate multiple pathways involved in PH pathogenesis have gained attention. This review focuses on peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. While the PPARγ receptor is best known as a master regulator of lipid and glucose metabolism, a growing body of literature demonstrates that activation of PPARγ exerts antiproliferative, antithrombotic, and vasodilatory effects on the vasculature, suggesting its potential efficacy as a PH therapeutic target.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed7609    
    Printed216    
    Emailed0    
    PDF Downloaded587    
    Comments [Add]    

Recommend this journal